Background: Gastric neoplasm, primarily adenocarcinoma, is an aggressive cancer with high mortality, often diagnosed late, leading to complications like metastasis. Effective drug combinations are vital to address disease heterogeneity, enhance efficacy, reduce resistance, and improve patient outcomes. Methods: The RAIN method integrated Graph SAGE to propose drug combinations, using a graph model with p-value-weighted edges connecting drugs, genes, and proteins. NLP and systematic literature review (PubMed, Scopus, etc.) validated proposed drugs, followed by network meta-analysis to assess efficacy, implemented in Python. Results: Oxaliplatin, fluorouracil, and trastuzumab were identified as effective, supported by 61 studies. Fluorouracil alone had a p-value of 0.0229, improving to 0.0099 with trastuzumab, and 0.0069 for the triple combination, indicating superior efficacy. Conclusion: The RAIN method, combining AI and network meta-analysis, effectively identifies optimal drug combinations for gastric neoplasm, offering a promising strategy to enhance treatment outcomes and guide health policy.

In this paper, we adapt a two species agent-based cancer model that describes the interaction between cancer cells and healthy cells on a uniform grid to include the interaction with a third species -- namely immune cells. We run six different scenarios to explore the competition between cancer and immune cells and the initial concentration of the immune cells on cancer dynamics. We then use coupled equation learning to construct a population-based reaction model for each scenario. We show how they can be unified into a single surrogate population-based reaction model, whose underlying three coupled ordinary differential equations are much easier to analyse than the original agent-based model. As an example, by finding the single steady state of the cancer concentration, we are able to find a linear relationship between this concentration and the initial concentration of the immune cells. This then enables us to estimate suitable values for the competition and initial concentration to reduce the cancer substantially without performing additional complex and expensive simulations from an agent-based stochastic model. The work shows the importance of performing equation learning from agent-based stochastic data for gaining key insights about the behaviour of complex cellular dynamics.

In 2021, cancer was the second leading cause of death in the European Union. Notably, while Europe constitutes only a tenth of the global population, it accounts for almost a quarter of the world's cancer cases, bearing an economic impact of approximately 100 billion annually. Belgian statistics further highlight that every step forward in cancer treatment and care could significantly alleviate the immense personal and societal burden. Globally, extensive efforts are made through a variety of innovative approaches with the ultimate objectives of better prevention, earlier detection, and improved patient outcomes and care. Personalized medicine is considered the holy grail of cancer care in most of these initiatives. Tailoring interventions to the unique characteristics of individual patients promises to revolutionize cancer care. Artificial intelligence (AI) plays a pivotal role in this transformative journey towards precision medicine, aiding researchers and healthcare professionals in accurately predicting cancer risks, enabling earlier diagnoses, and customizing treatment plans to meet individual needs.

Nanorobots are a promising development in targeted drug delivery and the treatment of neurological disorders, with potential for crossing the blood-brain barrier (BBB). These small devices leverage advancements in nanotechnology and bioengineering for precise navigation and targeted payload delivery, particularly for conditions like brain tumors, Alzheimer's disease, and Parkinson's disease. Recent progress in artificial intelligence (AI) and machine learning (ML) has improved the navigation and effectiveness of nanorobots, allowing them to detect and interact with cancer cells through biomarker analysis. This study presents a new reinforcement learning (RL) framework for optimizing nanorobot navigation in complex biological environments, focusing on cancer cell detection by analyzing the concentration gradients of surrounding biomarkers. We utilize a computer simulation model to explore the behavior of nanorobots in a three-dimensional space with cancer cells and biological barriers. The proposed method uses Q-learning to refine movement strategies based on real-time biomarker concentration data, enabling nanorobots to autonomously navigate to cancerous tissues for targeted drug delivery. This research lays the groundwork for future laboratory experiments and clinical applications, with implications for personalized medicine and less invasive cancer treatments. The integration of intelligent nanorobots could revolutionize therapeutic strategies, reducing side effects and enhancing treatment effectiveness for cancer patients. Further research will investigate the practical deployment of these technologies in medical settings, aiming to unlock the full potential of nanorobotics in healthcare.

The study presents a novel approach for quantifying cellular interactions in digital pathology using deep learning-based image cytometry. Traditional methods struggle with the diversity and heterogeneity of cells within tissues. To address this, we introduce the Spatial Interaction Potential (SIP) and the Co-Localization Index (CLI), leveraging deep learning classification probabilities. SIP assesses the potential for cell-to-cell interactions, similar to an electric field, while CLI incorporates distances between cells, accounting for dynamic cell movements. Our approach enhances traditional methods, providing a more sophisticated analysis of cellular interactions. We validate SIP and CLI through simulations and apply them to colorectal cancer specimens, demonstrating strong correlations with actual biological data. This innovative method offers significant improvements in understanding cellular interactions and has potential applications in various fields of digital pathology.

Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com. After losing his wife to colon cancer, a New York man has dedicated his life to fighting the disease and trying to protect other families from the same tragedy. Roy de Souza, now 54, and his wife, Aisha de Sequeira, had three young children when she was diagnosed with cancer in 2017. At the time, the family was living in India, where de Souza ran a technology company and his wife headed up an investment banking firm.

Computational models and simulations are not just appealing because of their intrinsic characteristics across spatiotemporal scales, scalability, and predictive power, but also because the set of problems in cancer biomedicine that can be addressed computationally exceeds the set of those amenable to analytical solutions. Agent-based models and simulations are especially interesting candidates among computational modelling strategies in cancer research due to their capabilities to replicate realistic local and global interaction dynamics at a convenient and relevant scale. Yet, the absence of methods to validate the consistency of the results across scales can hinder adoption by turning fine-tuned models into black boxes. This review compiles relevant literature to explore strategies to leverage high-fidelity simulations of multi-scale, or multi-level, cancer models with a focus on validation approached as simulation calibration. We argue that simulation calibration goes beyond parameter optimization by embedding informative priors to generate plausible parameter configurations across multiple dimensions.

Recently, Large Language Models (LLM) have demonstrated impressive capability to solve a wide range of tasks. However, despite their success across various tasks, no prior work has investigated their capability in the biomedical domain yet. To this end, this paper aims to evaluate the performance of LLMs on benchmark biomedical tasks. For this purpose, we conduct a comprehensive evaluation of 4 popular LLMs in 6 diverse biomedical tasks across 26 datasets. To the best of our knowledge, this is the first work that conducts an extensive evaluation and comparison of various LLMs in the biomedical domain. Interestingly, we find based on our evaluation that in biomedical datasets that have smaller training sets, zero-shot LLMs even outperform the current state-of-the-art fine-tuned biomedical models. This suggests that pretraining on large text corpora makes LLMs quite specialized even in the biomedical domain. We also find that not a single LLM can outperform other LLMs in all tasks, with the performance of different LLMs may vary depending on the task. While their performance is still quite poor in comparison to the biomedical models that were fine-tuned on large training sets, our findings demonstrate that LLMs have the potential to be a valuable tool for various biomedical tasks that lack large annotated data.

ChatGPT is a large language model developed by OpenAI. Despite its impressive performance across various tasks, no prior work has investigated its capability in the biomedical domain yet. To this end, this paper aims to evaluate the performance of ChatGPT on various benchmark biomedical tasks, such as relation extraction, document classification, question answering, and summarization. To the best of our knowledge, this is the first work that conducts an extensive evaluation of ChatGPT in the biomedical domain. Interestingly, we find based on our evaluation that in biomedical datasets that have smaller training sets, zero-shot ChatGPT even outperforms the state-of-the-art fine-tuned generative transformer models, such as BioGPT and BioBART. This suggests that ChatGPT's pre-training on large text corpora makes it quite specialized even in the biomedical domain. Our findings demonstrate that ChatGPT has the potential to be a valuable tool for various tasks in the biomedical domain that lack large annotated data.

Cancer is one of the most widespread diseases around the world with millions of new patients each year. Bladder cancer is one of the most prevalent types of cancer affecting all individuals alike with no obvious prototypical patient. The current standard treatment for BC follows a routine weekly Bacillus Calmette-Guerin (BCG) immunotherapy-based therapy protocol which is applied to all patients alike. The clinical outcomes associated with BCG treatment vary significantly among patients due to the biological and clinical complexity of the interaction between the immune system, treatments, and cancer cells. In this study, we take advantage of the patient's socio-demographics to offer a personalized mathematical model that describes the clinical dynamics associated with BCG-based treatment. To this end, we adopt a well-established BCG treatment model and integrate a machine learning component to temporally adjust and reconfigure key parameters within the model thus promoting its personalization. Using real clinical data, we show that our personalized model favorably compares with the original one in predicting the number of cancer cells at the end of the treatment, with 14.8% improvement, on average.